Clinical outcomes of radiofrequency catheter ablation of ventricular tachycardia in patients with hypertrophic cardiomyopathy |
| |
| Authors: | Jalaj Garg MD FACC FESC Jakrin Kewcharoen MD Kuldeep Shah MD Mohit Turagam MD Rahul Bhardwaj MD Tahmeed Contractor MD Ravi Mandapati MD FHRS Dhanunjaya Lakkireddy MD FHRS |
| |
| Affiliation: | 1. Division of Cardiology, Cardiac Arrhythmia Service, Loma Linda University Health, Loma Linda, California, USA;2. Department of Cardiovascular Medicine, Beaumont Hospital, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, USA;3. Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA;4. Kansas City Heart Rhythm Institute and Research Foundation, Kansas City, Kansas, USA |
| |
| Abstract: | Background Monomorphic ventricular tachycardia (VT) is rare in patients with hypertrophic cardiomyopathy (HCM), management of which is challenging. Limited data exists on the utility of catheter ablation for the treatment of VT in this population. Objectives We aimed to assess clinical outcomes of catheter ablation for VT in HCM patients. Methods A systematic search, without language restriction, using PubMed, EMBASE, SCOPUS, Google Scholar, and ClinicalTrials.gov was performed. The meta-analysis was performed using a meta-package for R version 4.0/RStudio version 1.2 and Freeman Tukey double arcsine method to establish the variance of raw proportions. Outcomes measured included (1) acute procedure success (defined as noninducible for clinical VT), (2) freedom from VT at follow-up, (3) mortality. Results This systematic review of six studies (three from the United States and three from Japan) incorporated a total of 68 drug-refractory HCM patients who underwent VT radiofrequency catheter ablation (mean age 57.6 ± 13.3 years, mean LVEF 45.8 ± 15.4%, 85% men, maximum septal wall thickness 17.4 ± 4.6 mm, and 32.3% with an apical aneurysm). Acute procedural success was achieved in 84.5% patients (95% confidence interval [CI]: 70.6%–95.2%) with 27.9% patients had recurrent VT requiring multiple ablations (median 1, IQR 1–3). During the follow-up period (18.3 ± 11.7 months), the pooled incidence of freedom from recurrent VT after index procedure was 70.2% (95% CI: 51.9%–86.2%), while after the last ablation was 82.8% (95% CI: 57%–99.2%). There were two deaths during follow-up, one from heart failure and one from SCD 0.8% (95% CI: 0%–5.8%). Conclusion The results of our pooled analysis demonstrated that catheter ablation for VT in HCM patients was associated with high acute procedural success, and reduced VT recurrence—findings comparable to previously published reports in other disease substrates. |
| |
| Keywords: | catheter ablation death hypertrophic cardiomyopathy ventricular tachycardia |
|
|
